The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

J&J’s Impella Heart Pumps Fail to Show Benefit in Major Clinical Trials

Key Facts

1Two large randomized clinical trials failed to demonstrate the benefits of J&J's miniaturized Impella heart pumps for patients with coronary artery blockages.

2One study found no benefit and potential long-term harm for patients receiving Impella during percutaneous coronary intervention (PCI).

3Another study showed that using the pump before reopening coronary arteries in STEMI patients did not reduce heart damage and led to more bleeding complications.

Create Free Account

Two major randomized clinical trials have failed to demonstrate the clinical benefits of Johnson & Johnson’s Impella heart pumps for patients with coronary artery blockages. The findings, presented at the American College of Cardiology meeting, revealed no significant advantage and potential long-term harm for patients undergoing percutaneous coronary intervention (PCI). Additionally, a second study showed that using the pump in STEMI patients did not reduce heart damage and was associated with higher rates of bleeding complications. These results challenge the routine clinical use of the Impella devices, which were a cornerstone of J&J’s $16.6 billion acquisition of Abiomed. Analysts suggest that the failure to meet primary endpoints could dampen growth expectations for J&J’s MedTech division and lead to reduced adoption by healthcare providers.